This signaling cascade provides a mechanistic explanation for the development of sorafenib resistance in HCC and suggests that concurrent blockade of the RhoA/ROCK/FAK pathway could be a viable strategy to enhance therapeutic efficacy. The gene discussed is PTK2; the disease is hepatocellular carcinoma.